Acanthamoeba keratitis (AK) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030


 Acanthamoeba keratitis (AK) is a rare infection of the cornea that, difficult to diagnose and treat properly, can be a sight-threatening disease. Acanthamoeba is currently divided into twenty-two different genotypes (T1–T22) based on 18s rRNA gene typing. Based on genotypes variations clinical presentation and response to therapy vary. The pathogen is transmitted through corneal contact with a contaminated substance. Most cases seen in humans seem to be associated with contaminated water, soil, or trauma to the eye. The progression of Acanthamoeba keratitis occurs in two main phases. An initial phase where infiltration is limited to the corneal epithelium, and a second phase where the parasite invades the underlying stroma. Once in the stroma, extensive damage to the collagen matrix occurs which provokes intense inflammation.

The estimated incidence of cases of Acanthamoeba keratitis with soft contact lens wearers ranges between 4.5 to 7.8 cases per 100,000 population.

 

The competitive landscape of Acanthamoeba keratitis (AK) includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Acanthamoeba keratitis (AK) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Acanthamoeba keratitis (AK) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Acanthamoeba keratitis (AK)  – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          Polihexanide     SIFI SpA           Phase 3

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033